Publications by authors named "S Noyola Cedillo"
Objective: Here we estimate the cost-effectiveness of olaparib in the Spanish National Health Service (SNHS) as adjuvant treatment of early germline mutations in the BRCA1/2 genes (gBRCAm) HER2-negative (HER2neg) breast cancer (BC) with high risk of recurrence.
Methods: A semi-Markov model was adapted to the Spanish healthcare setting, using the perspective of the SNHS, and a lifetime horizon. Two scenarios were compared: receiving olaparib versus standard of care (SoC) treatment.
Objective: The PAOLA-1 trial confirmed that adding olaparib to bevacizumab significantly increased clinical benefit following response to platinum-based chemotherapy in homologous recombination deficiency-positive ovarian cancer. The objective of this analysis was to determine the cost-effectiveness of olaparib plus bevacizumab compared with bevacizumab alone as maintenance treatment for patients with homologous recombination deficiency-positive advanced ovarian cancer from the Spanish National Health System perspective.
Methods: A lifetime partitioned survival model with four health states (progression-free, post-progression 1, post-progression 2, and death) and monthly cycles was developed.
Background: Neuromuscular blocking (NMB) agents are often administered to facilitate tracheal intubation and prevent patient movement during surgical procedures requiring the use of general anesthetics. Incomplete reversal of NMB, can lead to residual NMB, which can increase the risk of post-operative pulmonary complications. Sugammadex is indicated to reverse neuromuscular blockade induced by rocuronium or vecuronium in adults.
View Article and Find Full Text PDFArticle Synopsis
- Accurate HCV prevalence estimates are essential for formulating effective elimination policies, and a study was conducted in Spain to assess HCV prevalence and the cost-effectiveness of a screen-and-treat strategy.
- The study involved over 12,000 participants aged 20-74, revealing an overall anti-HCV prevalence of 1.2% and a detectable HCV-RNA prevalence of 0.3%, with higher infection rates in individuals aged 50-74.
- It concluded that implementing HCV screening programs is cost-effective, particularly for patients aged 50-54, and that approximately 25% of anti-HCV positive individuals have active infections, indicating a lower HCV burden than previously thought.